Beam Therapeutics Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
BEAM$25.15-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance at December 31, 2024 | 83,633,069 | $836 | $2,298,661 | $679 | $(1,566,631) | $733,545 |
| Cumulative effect of adoption of ASU 2025-07 | — | — | — | — | 5,404 | 5,404 |
| Purchase of common stock under ESPP | 90,436 | 1 | 1,500 | — | — | 1,501 |
| Issuance of common stock and pre-funded warrants, net of issuance costs of $30.8 million | 16,151,686 | 162 | 470,316 | — | — | 470,478 |
| Vesting of restricted common stock | 607,196 | 6 | (6) | — | — | — |
| Stock-based compensation | — | — | 26,682 | — | — | 26,682 |
| Exercise of common stock options | 74,707 | 1 | 718 | — | — | 719 |
| Other comprehensive income (loss) | — | — | — | (519) | — | (519) |
| Net loss | — | — | — | — | (108,330) | (108,330) |
| Balance at March 31, 2025 | 100,557,094 | $1,006 | $2,797,871 | $160 | $(1,669,557) | $1,129,480 |
Condensed Consolidated Statements of Stockholders’ Equity - Continued
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance at December 31, 2025 | 101,748,962 | $1,017 | $2,877,449 | $1,111 | $(1,641,219) | $1,238,358 |
| Purchase of common stock under ESPP | 74,518 | 1 | 1,509 | — | — | 1,510 |
| Vesting of restricted common stock | 720,697 | 7 | (7) | — | — | — |
| Stock-based compensation | — | — | 19,044 | — | — | 19,044 |
| Exercise of common stock options | 197,671 | 2 | 2,023 | — | — | 2,025 |
| Other comprehensive income (loss) | — | — | — | (2,181) | — | (2,181) |
| Net loss | — | — | — | — | (94,318) | (94,318) |
| Balance at March 31, 2026 | 102,741,848 | $1,027 | $2,900,018 | $(1,070) | $(1,735,537) | $1,164,438 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.